Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis

Hepatology

Social Determinants of Health Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease Prevalence and Severity: A Systematic Review and Meta-analysis

Am J Gastroenterol

Abu-Rumaileh M, Dhoop S, Pace J, Qapaja T, Martinez ME, Tincopa M, Loomba R

doi: 10.14309/ajg.0000000000003421

Hepatology

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

BMC Gastroenterol

Shin WY, Kang ES, Oh YH, Sha M, Xia Q, Jeong S, Cho Y

doi: 10.1186/s12876-025-03814-1

Celiac Disease

Association between celiac disease and risk of kidney diseases: a systematic review and meta-analysis

Minerva Gastroenterol (Torino)

Rathore SS, Shaikh SP, Zaidi HR, Salako GO, Saravanan CR, Kuranga RR, Yagateela N, Bandala ST, Jeswani BM

doi: 10.23736/S2724-5985.25.03733-7

Further Publications

Neighborhood social determinants of health are associated with metabolic dysfunction-associated steatotic liver disease outcomes

Clin Gastroenterol Hepatol

Faulkner CS, Aboona MB, Surendra L, Rangan P, Ng CH, Huang DQ, Muthiah M, Kim D, Fallon MB, Noureddin M, Chen VL, Kardashian A, Wijarnpreecha K

doi: 10.1016/j.cgh.2024.10.019

Hepatology

Longitudinal response to standard of care in pediatric metabolic dysfunction-associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes

Hepatology

Newton KP, Jayasekera D, Blackford AL, Behling C, Wilson LA, Fishbein MH, Molleston JP, Xanthakos SA, Vos MB, Schwimmer JB, NASH CRN

doi: 10.1097/HEP.0000000000001216

Hepatitis

Pharmacological Strategies for the Management of Severe Alcohol-associated Hepatitis: A Systematic Review and Meta-analysis

Clin Gastroenterol Hepatol

Islam AH, Alvizuri C, Desalegn H, Stephenson E, Idalsoaga F, Diaz LA, MacDonald JK, Im GY, Singal AK, Jairath V, Khan MQ, Arab JP

doi: 10.1016/j.cgh.2025.05.016

Hepatology

Optimal population screening strategies for liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease

Am J Gastroenterol

Kim WR, Mannalithara A, Charu V, Chung N, Kwong A, Kwo PY, Torok NJ, Asch SM, Kim SH

doi: 10.14309/ajg.0000000000003268

Hepatology

Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data

Hepatology

Ng WH, Yeo YH, Kim H, Seki E, Rees J, Ma KS, Moylan CA, Rodriquez LM, Abdelmalek M, Villanueva A, Noureddin M, Yang JD

doi: 10.1097/HEP.0000000000001333

Hepatology

The liver-brain axis in metabolic dysfunction-associated steatotic liver disease

Lancet Gastroenterol Hepatol

Mikkelsen ACD, Kjærgaard K, Schapira AHV, Mookerjee RP, Thomsen KL

doi: 10.1016/S2468-1253(24)00320-0

Related content

Social Determinants of Health Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease Prevalence and Severity: A Systematic Review and Meta-analysis

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

Association between celiac disease and risk of kidney diseases: a systematic review and meta-analysis

Neighborhood social determinants of health are associated with metabolic dysfunction-associated steatotic liver disease outcomes

Longitudinal response to standard of care in pediatric metabolic dysfunction-associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes

Pharmacological Strategies for the Management of Severe Alcohol-associated Hepatitis: A Systematic Review and Meta-analysis

Optimal population screening strategies for liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease

Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data

The liver-brain axis in metabolic dysfunction-associated steatotic liver disease